Vineet Datta, Senior Director of Global Strategy at Datar Cancer Genetics Limited , shared a post on LinkedIn:
“Just returning from an insightful few days in Dubai at the EOS 2025 Annual Meeting, where Dr. Sewanti Limaye, MBBS, MD, MS delivered a thought‑provoking session on the evolving role of liquid biopsy in multi‑cancer early detection.
With the increasing availability of complex datasets, it’s essential to weigh the remarkable promise of these emerging technologies, while being mindful of the potential risks they may introduce. Dr. Limaye shared data on TruCheck, a circulating tumor cell–based (CTC), non‑invasive blood test for early cancer detection. Her presentation provided a comprehensive view of liquid biopsy’s broad applications, its challenges, and the implications for the future of cancer screening. Previously, she has lead the CTC driven early prostate cancer detection research that successfully culminated in a USFDA Breakthrough Designation for the blood based solution.
A big thank you to Dr. Limaye for such an engaging and impactful talk!
Thank you Prof.Humaid Al-Shamsi for the gracious invite and hospitality.”
More posts featuring Vineet Datta.
